Advisors Asset Management, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Advisors Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$17.09 - $24.89 $1,709 - $2,489	-100 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $4,306 - $7,357	-298 Reduced 74.87%	100 $2,000
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $5,680 - $8,302	-285 Reduced 41.73%	398 $9,000
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $6,749 - $8,843	-265 Reduced 27.95%	683 $19,000
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $2,247 - $2,915	-75 Reduced 7.33%	948 $31,000
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $7,733 - $9,909	236 Added 29.99%	1,023 $36,000
Q4 2018 Jan 31, 2019	BUY	$30.84 - $49.51 $4,996 - $8,020	162 Added 25.92%	787 $26,000
Q3 2018 Nov 15, 2018	BUY	$42.7 - $56.55 $15,628 - $20,697	366 Added 141.31%	625 $31,000
Q2 2018 Aug 22, 2018	SELL	$44.1 - $59.85 $21.3 Million - $28.9 Million	-482,676 Reduced 99.95%	259 $16,000
Q2 2018 Aug 15, 2018	BUY	$44.1 - $59.85 $21.3 Million - $28.9 Million	482,883 Added 928621.12%	482,935 $16,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $1,931 - $2,438	52 New	52 $2,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.